iHuman Q2 Revenue Drops 18% as China's Newborn Decline Hits Demand
IH is trading near its 52-week low of $1.11 (5.4% above the low).
Summary
iHuman's Q2 2026 revenue fell 18% year-over-year to RMB 173.4 million, driven by a drop in China's newborn population and more conservative consumer spending. The company swung to a net loss of RMB17.5 million (US$2.6 million) from a profit a year earlier, with operating loss of RMB20.8 million and operating expenses climbing to RMB 132 million due to higher sales and marketing spend. Average total MAUs were 20.72 million. Gross margin held at 64.1%, but the top-line decline and lack of guidance raise concerns about the company's ability to stabilize growth. The results reflect structural headwinds in China's edtech market, where demographic trends are reducing the addressable user base. No specific financial guidance was provided, leaving investors without a clear path to recovery.
Updated with an SEC 6-K filing · What changed
Updates
· SEC 6-K — iHuman's Q2 net loss was RMB17.5 million (US$2.6 million), with operating loss of RMB20.8 million and average total MAUs of 20.72 million.
At the time of this announcement, IH was trading at $1.17 on NYSE in the Technology sector, with a market capitalization of approximately $58.8M. The 52-week trading range was $1.11 to $3.09. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.